(FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q9)Sep 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -31.39%6.45B | -25.86%5.19B | -35.11%2.68B | -42.31%1.27B | 9.46%9.39B | 17.96%7B | 4.76%4.13B | --2.21B | -3.94%8.58B | --5.93B |
Operating income | -31.39%6.45B | -35.11%2.68B | 9.46%9.39B | 4.76%4.13B | -3.94%8.58B | |||||
Cost of sales | 31.15%-6.34B | ---- | 34.78%-2.64B | ---- | -10.10%-9.2B | ---- | -4.34%-4.04B | ---- | 5.45%-8.36B | ---- |
Operating expenses | 31.15%-6.34B | 34.78%-2.64B | -10.10%-9.2B | -4.34%-4.04B | 5.45%-8.36B | |||||
Gross profit | -42.79%109.82M | -51.49%39.62M | -14.46%191.96M | 31.07%81.68M | 135.71%224.41M | |||||
Selling expenses | 39.57%-5.39M | ---- | -68.14%-5.68M | ---- | 34.29%-8.91M | ---- | 5.51%-3.38M | ---- | 10.52%-13.56M | ---- |
Administrative expenses | 12.65%-156.91M | ---- | 2.35%-90.18M | ---- | -3.29%-179.64M | ---- | 7.56%-92.35M | ---- | 2.41%-173.92M | ---- |
Research and development expenses | 23.30%-57.11M | ---- | 29.34%-26.46M | ---- | 30.00%-74.45M | ---- | 40.27%-37.45M | ---- | 38.31%-106.36M | ---- |
Impairment and provision | -64.66%-138.71M | ---- | -250.88%-50.74M | ---- | -399.92%-84.24M | ---- | ---14.46M | ---- | 43.17%-16.85M | ---- |
-Impairment of property, machinery and equipment | -31.84%-4.88M | ---- | ---- | ---- | 69.58%-3.7M | ---- | ---- | ---- | 58.95%-12.17M | ---- |
-Other impairment is provision | -66.17%-133.82M | ---- | -250.88%-50.74M | ---- | -1,621.18%-80.53M | ---- | ---14.46M | ---- | ---4.68M | ---- |
Operating interest expense | -104.88%-60.6M | ---- | -224.80%-23.55M | ---- | -233.20%-29.58M | ---- | -84.60%-7.25M | ---- | 27.14%-8.88M | ---- |
Special items of operating profit | 73.05%229.51M | ---- | 109.02%132.73M | ---- | -20.32%132.63M | ---- | -16.95%63.5M | ---- | 4.58%166.45M | ---- |
Operating profit | -51.97%-79.39M | -149.94%-24.27M | -173.29%-52.24M | 69.00%-9.71M | 146.51%71.28M | |||||
Share of profits of associates | 88.85%-344K | ---- | 20.99%-3.25M | ---- | -176.19%-3.09M | ---- | -4,178.13%-4.11M | ---- | -126.13%-1.12M | ---- |
Share of profit from joint venture company | -362.62%-20.18M | ---- | 59.45%-2.09M | ---- | ---4.36M | ---- | ---5.15M | ---- | ---- | ---- |
Earning before tax | -67.39%-99.9M | -56.06%-29.6M | -185.07%-59.68M | 39.62%-18.97M | 147.09%70.16M | |||||
Tax | -67.61%-20.87M | ---- | -316.77%-20.23M | ---- | 9.35%-12.45M | ---- | -257.37%-4.86M | ---- | 44.75%-13.74M | ---- |
After-tax profit from continuing operations | -67.43%-120.77M | -109.19%-49.84M | -227.85%-72.14M | 15.91%-23.82M | 132.46%56.42M | |||||
Earning after tax | -67.43%-120.77M | -82.52%-70.2M | -109.19%-49.84M | -178.27%-52.32M | -227.85%-72.14M | -470.99%-38.46M | 15.91%-23.82M | -18.8M | 132.46%56.42M | -6.74M |
Minority profit | -232.14%-93K | ---- | 520.93%181K | ---- | -129.47%-28K | ---- | 70.34%-43K | ---- | -7.77%95K | ---- |
Profit attributable to shareholders | -67.36%-120.68M | -110.33%-50.02M | -228.01%-72.11M | 15.63%-23.78M | 132.38%56.33M | |||||
Basic earnings per share | -67.03%-0.0152 | -100.00%-0.006 | -30.00%-0.0091 | 0.00%-0.003 | 67.14%-0.007 | |||||
Diluted earnings per share | -67.03%-0.0152 | -100.00%-0.006 | -30.00%-0.0091 | -0.003 | -0.007 | |||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |
Auditor | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- | -- | -- | Deloitte & Touche Tohmatsu Certified Public Accountants | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data